Drugs / H20174089
H20174089
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT05756595 Background | Jul 2020 → Dec 2022 | herpes zoster | Dove Medical Press Ltd | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H20174089 | “the high molecular Hyaluronan injection (sodium hyaluronate injection, H20174089)” NCT05756595 ↗ |
| Known as | HA35(L20200708MP07707, Ministry of Health, Mongolia) was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05756595 ↗ |
| Known as | high-molecular-weight HA injectable solution | “high-molecular-weight HA injectable solution (H20174089)” NCT05756595 ↗ |
| Known as | sodium hyaluronate | “the high molecular Hyaluronan injection (sodium hyaluronate injection, H20174089)” NCT05756595 ↗ |
| Route | Other | “100 mg Hyaluronan is locally injected at the pain point or where the nerve trunk is innervated by the pain point.” NCT05756595 ↗ |